Synaptogenix Inc (SNPX) - Net Assets
Based on the latest financial reports, Synaptogenix Inc (SNPX) has net assets worth $17.96 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($19.79 Million) and total liabilities ($1.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Synaptogenix Inc (SNPX) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.96 Million |
| % of Total Assets | 90.77% |
| Annual Growth Rate | -20.34% |
| 5-Year Change | 31.88% |
| 10-Year Change | N/A |
| Growth Volatility | 222.48 |
Synaptogenix Inc - Net Assets Trend (2018–2024)
This chart illustrates how Synaptogenix Inc's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Synaptogenix Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Synaptogenix Inc (2018–2024)
The table below shows the annual net assets of Synaptogenix Inc from 2018 to 2024. For live valuation and market cap data, see SNPX market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.78 Million | -73.51% |
| 2023-12-31 | $25.58 Million | -27.76% |
| 2022-12-31 | $35.41 Million | +5.62% |
| 2021-12-31 | $33.53 Million | +552.52% |
| 2020-12-31 | $5.14 Million | -70.50% |
| 2019-12-31 | $17.42 Million | -34.32% |
| 2018-12-31 | $26.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Synaptogenix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4716913231790700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $137.00 | 0.00% |
| Other Comprehensive Income | $5.70K | 0.00% |
| Other Components | $53.03 Trillion | 904.43% |
| Total Equity | $5.86 Trillion | 100.00% |
Synaptogenix Inc Competitors by Market Cap
The table below lists competitors of Synaptogenix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bolt Biotherapeutics
NASDAQ:BOLT
|
$8.09 Million |
|
Jet.AI Inc.
NASDAQ:JTAI
|
$8.10 Million |
|
EA Holdings Bhd
KLSE:0154
|
$8.10 Million |
|
Eros International Media Limited
NSE:EROSMEDIA
|
$8.10 Million |
|
The Agency Group Australia Ltd
AU:AU1
|
$8.09 Million |
|
ODIGMA CONSULTANCY SOLUTIONS LTD
NSE:ODIGMA
|
$8.09 Million |
|
Olive Resource Capital Inc
V:OC
|
$8.09 Million |
|
AB Effectenbeteiligungen AG
STU:JPH
|
$8.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Synaptogenix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 25,584,198 to 5,863,682,000,000, a change of 5,863,656,415,802 (22919055.0%).
- Net loss of 12,768,549 reduced equity.
- Dividend payments of 950,918,000,000 reduced retained earnings.
- Share repurchases of 8,633,371 reduced equity.
- New share issuances of 4,463,000 increased equity.
- Other comprehensive income increased equity by 4,800.
- Other factors increased equity by 6,814,591,349,922.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.77 Million | -0.0% |
| Dividends Paid | $950.92 Billion | -16.22% |
| Share Repurchases | $8.63 Million | -0.0% |
| Share Issuances | $4.46 Million | +0.0% |
| Other Comprehensive Income | $4.80K | +0.0% |
| Other Changes | $6.81 Trillion | +116.22% |
| Total Change | $- | 22919055.02% |
Book Value vs Market Value Analysis
This analysis compares Synaptogenix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $111.48 | $5.82 | x |
| 2019-12-31 | $346.28 | $5.82 | x |
| 2020-12-31 | $102.15 | $5.82 | x |
| 2021-12-31 | $167.14 | $5.82 | x |
| 2022-12-31 | $126.68 | $5.82 | x |
| 2023-12-31 | $54.89 | $5.82 | x |
| 2024-12-31 | $4752923.73 | $5.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Synaptogenix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (-0.00%) is above the historical average (-68.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -41.56% | 0.00% | 0.00x | 1.11x | $-13.67 Million |
| 2019 | -84.71% | 0.00% | 0.00x | 1.03x | $-16.50 Million |
| 2020 | -277.32% | 0.00% | 0.00x | 1.31x | $-14.76 Million |
| 2021 | -37.59% | 0.00% | 0.00x | 1.06x | $-15.96 Million |
| 2022 | -15.41% | 0.00% | 0.00x | 1.09x | $-9.00 Million |
| 2023 | -23.60% | 0.00% | 0.00x | 1.22x | $-8.60 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-586.38 Billion |
Industry Comparison
This section compares Synaptogenix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Synaptogenix Inc (SNPX) | $17.96 Million | -41.56% | 0.10x | $8.09 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Synaptogenix Inc
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X synd… Read more